Donald Milder Biography and Net Worth

Director of Inari Medical


Donald Milder
Chairman of the Board
Donald Milder has served as a member of our board of directors since September 2011 and as its Chair since December 2019. In 1999, Mr. Milder co-founded Versant Venture Management, LLC, or Versant, where he has been a Managing Director since its inception. Versant is a venture capital firm that invests in medical devices, biotechnology, life science, pharmaceuticals and healthcare sectors. Previously, Mr. Milder was a Managing Director with CPVP Management LP from August 1989 to November 1999, where he was responsible for their healthcare investments. Prior to this, Mr. Milder was the Chief Executive Officer of Infusion Systems Corporation from 1984 to 1989. He currently serves as a board member for Eclipse Regenesis, Inc., Okami, NeoSeq Ltd. and Ceres Foundation. Mr. Milder received a B.A. from Union College and an M.B.A. from Harvard Business School.

What is Donald B. Milder's net worth?

The estimated net worth of Donald B. Milder is at least $167.99 million as of November 7th, 2023. Mr. Milder owns 3,029,614 shares of Inari Medical stock worth more than $167,992,096 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Milder may own. Learn More about Donald B. Milder's net worth.

How do I contact Donald B. Milder?

The corporate mailing address for Mr. Milder and other Inari Medical executives is 9 Parker Suite 100, Irvine CA, 92618. Inari Medical can also be reached via phone at 877-923-4747 and via email at [email protected]. Learn More on Donald B. Milder's contact information.

Has Donald B. Milder been buying or selling shares of Inari Medical?

Donald B. Milder has not been actively trading shares of Inari Medical in the last ninety days. Most recently, on Tuesday, November 7th, Donald B. Milder bought 54,000 shares of Inari Medical stock. The stock was acquired at an average cost of $53.44 per share, with a total value of $2,885,760.00. Following the completion of the transaction, the director now directly owns 3,029,614 shares of the company's stock, valued at $161,902,572.16. Learn More on Donald B. Milder's trading history.

Who are Inari Medical's active insiders?

Inari Medical's insider roster includes Rebecca Chambers (Director), Mitch Hill (CFO), William Hoffman (CEO), Andrew Hykes (CEO, President & Director), Donald Milder (Director), Kirk Nielsen (Director), and Thomas Tu (Insider). Learn More on Inari Medical's active insiders.

Are insiders buying or selling shares of Inari Medical?

In the last year, insiders at the sold shares 26 times. They sold a total of 562,744 shares worth more than $27,798,968.16. The most recent insider tranaction occured on December, 20th when CEO Andrew Hykes sold 3,000 shares worth more than $165,870.00. Insiders at Inari Medical own 10.6% of the company. Learn More about insider trades at Inari Medical.

Information on this page was last updated on 12/20/2024.

Donald B. Milder Insider Trading History at Inari Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2023Buy54,000$53.44$2,885,760.003,029,614View SEC Filing Icon  
11/15/2022Sell7,000$80.13$560,910.003,185,614View SEC Filing Icon  
10/18/2022Sell7,000$80.07$560,490.003,192,614View SEC Filing Icon  
9/15/2022Sell7,000$80.25$561,750.003,199,614View SEC Filing Icon  
8/15/2022Sell7,000$80.78$565,460.003,206,614View SEC Filing Icon  
8/2/2022Sell21,000$80.44$1,689,240.003,423,614View SEC Filing Icon  
4/18/2022Sell7,000$86.89$608,230.003,654,614View SEC Filing Icon  
3/16/2022Sell7,000$80.18$561,260.00View SEC Filing Icon  
2/23/2022Sell100$80.00$8,000.00View SEC Filing Icon  
2/15/2022Sell335$80.01$26,803.35View SEC Filing Icon  
2/9/2022Sell400$80.06$32,024.00View SEC Filing Icon  
12/10/2021Sell7,000$79.00$553,000.00View SEC Filing Icon  
10/8/2021Sell7,000$79.33$555,310.00View SEC Filing Icon  
9/10/2021Sell7,000$81.02$567,140.00244,203View SEC Filing Icon  
8/10/2021Sell7,000$90.64$634,480.00244,203View SEC Filing Icon  
7/9/2021Sell7,000$92.72$649,040.00244,203View SEC Filing Icon  
5/10/2021Sell7,000$90.43$633,010.00239,841View SEC Filing Icon  
4/9/2021Sell7,000$112.19$785,330.00239,841View SEC Filing Icon  
3/10/2021Sell7,000$116.64$816,480.00239,841View SEC Filing Icon  
1/11/2021Sell7,000$84.59$592,130.00239,841View SEC Filing Icon  
12/10/2020Sell7,000$68.09$476,630.00239,841View SEC Filing Icon  
See Full Table

Donald B. Milder Buying and Selling Activity at Inari Medical

This chart shows Donald B Milder's buying and selling at Inari Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inari Medical Company Overview

Inari Medical logo
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $55.45
Low: $53.49
High: $55.82

50 Day Range

MA: $50.12
Low: $42.20
High: $58.21

2 Week Range

Now: $55.45
Low: $36.73
High: $66.61

Volume

1,874,948 shs

Average Volume

998,000 shs

Market Capitalization

$3.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97